Compare FEIM & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FEIM | ANL |
|---|---|---|
| Founded | 1961 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Electrical Products | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 439.6M | 406.5M |
| IPO Year | 1994 | 2022 |
| Metric | FEIM | ANL |
|---|---|---|
| Price | $48.95 | $8.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $42.50 | $16.00 |
| AVG Volume (30 Days) | ★ 188.0K | 185.4K |
| Earning Date | 03-11-2026 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 316.95 | N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | ★ $69,811,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $21.73 | N/A |
| P/E Ratio | $113.95 | ★ N/A |
| Revenue Growth | ★ 26.30 | N/A |
| 52 Week Low | $14.41 | $0.88 |
| 52 Week High | $61.47 | $12.09 |
| Indicator | FEIM | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 53.65 | 59.18 |
| Support Level | $47.54 | $1.36 |
| Resistance Level | $59.68 | $9.98 |
| Average True Range (ATR) | 3.39 | 0.86 |
| MACD | 0.43 | 0.03 |
| Stochastic Oscillator | 88.79 | 81.20 |
Frequency Electronics Inc is engaged in the design, development, and manufacture of high-precision timing, and frequency control products for space, air, sea, and terrestrial applications. The company has FEI-NY and FEI-Zyfer reportable segments. It derives the majority of its revenues from the FEI-NY segment. FEI-NY segment operations consist principally of precision time and frequency control products used in three principal markets namely communication satellites (both commercial and U.S. Government-funded); terrestrial cellular telephone or other ground-based telecommunication stations; and other components and systems for the U.S. military.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.